文献速递分子诊断临床微生物

NxTAG呼吸道病原体面板v2的多中心高通量多重检测评估

High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay.
PubMed 文献 · J Clin Microbiol · 2026-03-19

这项多中心研究在美国五个临床中心评估了NxTAG呼吸道病原体面板v2(RPPv2)检测21种病毒和细菌呼吸道病原体的临床与分析性能,共分析2,145份鼻咽拭子标本。结果显示,单次复测后99.7%的标本获得有效结果,所有病毒和细菌分析物的阴性符合率均≥99.2%,跨站点和操作者的重现性为99.9%。

要点

  • 单次复测后99.7%的标本获得有效结果,新鲜与冷冻标本间性能差异极小。
  • 18种病毒靶标中15种达到≥95%的阳性符合率(PPA)。
  • 所有病毒和细菌分析物的阴性符合率(NPA)均≥99.2%,重现性为99.9%。

核心结论

  • NxTAG RPPv2展现出高准确性、重现性和操作效率,支持其用于呼吸道感染的快速可靠诊断。

研究设计与样本

  • 多中心研究在美国五个临床中心分析2,145份鼻咽拭子标本,包括前瞻性入组和存档标本。
  • 以FDA批准的分子检测和双向测序为参照,并使用人工构建标本补充低流行率靶标。

主要发现

  • 单次复测后99.7%的标本获得有效结果,新鲜与冷冻标本间性能差异极小。
  • 18种病毒靶标中15种(一种病毒靶标无临床阳性标本可供分析)在前瞻性和预选组中达到≥95%的阳性符合率(PPA)。
  • 细菌靶标中,肺炎支原体和肺炎衣原体的PPA分别为92.3%和100%。
  • 副流感病毒4型的PPA较低,为90.3%。
  • 所有病毒和细菌分析物的阴性符合率(NPA)均≥99.2%,跨站点和操作者的重现性为99.9%。

关键数值与推荐

  • 病毒靶标:18种中15种达到≥95%的PPA。
  • 细菌靶标:肺炎支原体PPA为92.3%,肺炎衣原体PPA为100%。
  • 副流感病毒4型PPA为90.3%。
  • 所有分析物NPA均≥99.2%。
  • 重现性为99.9%。

临床怎么用

  • 该高通量多重分子检测可用于呼吸道感染的快速可靠诊断,支持抗菌药物管理。

局限性

  • 一种病毒靶标无临床阳性标本可供分析,使用人工构建标本补充低流行率靶标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Respiratory tract infections remain a major cause of global morbidity, highlighting the need for rapid and accurate diagnostic testing. This multicenter study evaluated the clinical and analytical performance of the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput multiplex molecular assay designed to detect 21 viral and bacterial respiratory pathogens. A total of 2,145 nasopharyngeal swab specimens, including both prospectively enrolled and archived specimens, were analyzed across five U.S. clinical sites. The NxTAG RPPv2 was assessed against FDA-cleared molecular assays and bi-directional sequencing, with contrived specimens used to supplement low-prevalence targets. Valid results were obtained for 99.7% of specimens after a single retest, with minimal performance differences between fresh and frozen specimens. Among viral targets, 15 of 18 (one viral target did not have clinical positive specimens for analysis) achieved ≥95% positive percent agreement (PPA) across the prospective and pre-selected arms. For bacterial targets, Mycoplasma pneumoniae and Chlamydia pneumoniae showed PPA values of 92.3% and 100%, respectively. Lower PPA values were observed for parainfluenza 4 (90.3%). Negative percent agreement (NPA) was consistently high across targets, with all viral and bacterial analytes achieving ≥99.2%. Reproducibility across sites and operators was 99.9%. Overall, the NxTAG RPPv2 demonstrated high accuracy, reproducibility, and operational efficiency, supporting its clinical utility for rapid and reliable diagnosis of respiratory tract infections. IMPORTANCE: Respiratory infections remain a major global health challenge, particularly during seasonal epidemics and pandemics. Rapid and accurate pathogen detection is essential to guide treatment decisions, limit transmission, and reduce unnecessary antibiotic use. This multicenter study evaluated the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput molecular assay capable of detecting 22 common viral and bacterial respiratory pathogens from a single sample. The panel demonstrated high accuracy, reproducibility, and reliability across multiple clinical sites and sample types, including both fresh and frozen specimens. These findings support the NxTAG RPPv2 as a comprehensive, efficient diagnostic tool that can support respiratory infection diagnosis and contribute to multifaceted antimicrobial stewardship efforts.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Nielsen MC, Ren P, Kavuri SB, et al. High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay. J Clin Microbiol. 2026. PMID: 41854425. doi:10.1128/jcm.01743-25

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。